Fuji Pharma Co., Ltd.

Tokyo Stock Exchange 4554.T

Fuji Pharma Co., Ltd. EBITDA for the year ending September 30, 2024: USD 84.54 M

Fuji Pharma Co., Ltd. EBITDA is USD 84.54 M for the year ending September 30, 2024, a 67.48% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Fuji Pharma Co., Ltd. EBITDA for the year ending September 30, 2023 was USD 50.48 M, a 12.04% change year over year.
Fuji Pharma Co., Ltd. EBITDA for the year ending September 30, 2022 was USD 45.05 M, a -8.07% change year over year.
Fuji Pharma Co., Ltd. EBITDA for the year ending September 30, 2021 was USD 49.01 M, a -0.56% change year over year.
Fuji Pharma Co., Ltd. EBITDA for the year ending September 30, 2020 was USD 49.28 M, a -15.47% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Tokyo Stock Exchange: 4554.T

Fuji Pharma Co., Ltd.

CEO	Mr. Toyoyuki Kamide
IPO Date	Feb. 22, 2010
Location	Japan
Headquarters	5-7 Sanban-cho
Employees	1,621
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Medical Instruments Personal Care

Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years